CAMBRIDGE, Mass.--(BUSINESS WIRE)--Results of a phase IV, open label, head-to-head study of intramuscular AVONEX and high-dose, high-frequency subcutaneous Rebif® (interferon beta-1a) provide clinical evidence that the two drugs show similar efficacy over 18 to 30 months of continued therapy in patients with relapsing-remitting multiple sclerosis (RRMS). These data are published in the April 2008 issue of the Current Medical Research and Opinion journal.
